Biologics for Severe Asthma and COPD: Pulmonology in 2026
DocSite AI Team
April 28, 2026
A decade ago, severe asthma meant chronic oral steroids and frequent ER visits. By 2026, monoclonal antibodies targeting type-2 inflammation have made oral-steroid-free remission a realistic goal for the right patients — and the COPD biologic story has finally arrived.
Where biologics now have clear evidence
- Severe eosinophilic asthma — mepolizumab, benralizumab, reslizumab give 50%+ reductions in exacerbations in the right patients.
- Severe asthma with type-2 inflammation — dupilumab (anti-IL-4Rα) is broadly effective, including patients with comorbid atopic dermatitis or chronic rhinosinusitis with nasal polyps.
- Tezepelumab (anti-TSLP) — works across phenotypes including low-eosinophil severe asthma, the previously hardest-to-treat group.
The COPD biologic breakthrough
- Dupilumab showed significant exacerbation reduction in COPD with type-2 inflammation in 2024 — first biologic with positive Phase 3 data in COPD.
- Eosinophilic phenotype in COPD (~30% of patients) is increasingly recognised as a treatable trait.
- Approval pathways for COPD biologics are progressing in 2025–2026.
What patients should know
- Inhaler technique and adherence still drive most asthma outcomes — biologics don't rescue poor inhaler use.
- Phenotyping with blood eosinophils, FeNO, and IgE is essential to match the right biologic to the right patient.
- Cost and access remain real barriers — specialised severe asthma clinics are the right entry point.
What this means for patients and practising clinicians
If your asthma still produces frequent ER visits or you've been on chronic oral steroids for more than three months, you likely meet criteria for a severe asthma clinic referral. The 2026 toolkit can change your life — but only if you get phenotyped properly first.
*This article was drafted by the DocSite AI Team and reviewed for clinical accuracy. It is general medical information, not personal medical advice. For decisions about your own care, please consult a qualified specialist on DocSite.*
Frequently Asked Questions
Will biologics cure my asthma?
They control it remarkably well in responders, often allowing oral steroid withdrawal. They don't cure the underlying airway disease.
How are biologics given?
Most are subcutaneous injections every 2–8 weeks, often self-administered at home after initial supervised dosing.
Are they safe long-term?
Multi-year safety data is now available for most agents and is reassuring. Vaccination and infection monitoring remain prudent.
Book a consult with your Specialist Pulmonologist
Find practising pulmonologists on DocSite and book directly — no middlemen, no paid rankings.
Find a Pulmonologist